Dr Crispin Thomas Hiley

Discover Dr. Crispin Hiley: Leading Private Oncologist in London

Dr. Crispin Hiley is an internationally acclaimed oncology expert known for combining advanced scientific research with compassionate patient care. As an Associate Professor in Oncology at University College London and a Consultant Oncologist at University College London Hospital, Dr. Hiley stands at the cutting edge of cancer treatment and research. He also serves as the Clinical Director for Lung Cancer at GenesisCare UK, which provides private healthcare across 14 specialist centers in the UK.

Comprehensive and Personalized Cancer Care

Dr. Hiley is committed to delivering personalized care tailored to each patient’s unique needs. He offers private consultations in London and provides comprehensive chemotherapy and radiotherapy services across the UK. For those who prefer the comfort of their home, Dr. Hiley can arrange for chemotherapy to be administered at home when appropriate.

Expert in Lung Cancer Treatment

Specializing in non-surgical treatments for lung cancer, Dr. Hiley is an authority in:

- Chemotherapy

- Immunotherapy

- Targeted Therapy

- Advanced Radiotherapy Techniques, including:

- Volumetric Arc Therapy (VMAT)

- Intensity Modulated Radiotherapy (IMRT)

- Image Guided Radiotherapy (IGRT)

- Proton Therapy

- Stereotactic Radiotherapy (SBRT)

Dr. Hiley’s research includes significant contributions to understanding resistance mechanisms to EGFR inhibitors like Osimertinib and immunotherapies such as Atezolizumab and Pembrolizumab.

[Watch Dr. Hiley Discuss His Research](https://youtu.be/8VqLkjbgtmA?si=hHiD0fOuSCzABUQv)

As the UCLH Lead for Lung Proton Therapy, Dr. Hiley was the first oncologist in the UK to treat lung cancer patients with this innovative technology. He is also the chief investigator of the HIT-MESO trial, which examines the use of Proton Beam Radiotherapy for mesothelioma patients. Through his role with Proton International@UCLH, he offers advanced proton therapy treatments for private patients.

[Learn More About the HIT-MESO Trial](https://crukradnet.colcc.ac.uk/2022/08/11/new-clinical-trial-hemithoracic-irradiation-with-proton-therapy-in-malignant-pleural-mesothelioma-hit-meso/)

Advanced Radiotherapy for Multiple Cancer Types

Dr. Hiley’s expertise extends beyond lung cancer. He specializes in stereotactic radiotherapy (SBRT) for oligo metastatic and oligo progressive diseases in various cancers, including:

- Breast Cancer

- Prostate Cancer

- Colorectal Cancer

- Gynecological Cancers

- Sarcomas

- Lung Cancer

He utilizes the latest technology, including MRI-guided SABR with the ViewRay MRIdian system, to treat challenging tumors. Additionally, Dr. Hiley offers reirradiation therapy for patients who have previously undergone radiotherapy.

[Read More on Stereotactic Radiotherapy](https://www.genesiscare.com/uk/specialists/about-us/innovations-blog/stereotactic-radiotherapy-for-the-management-of-early-stage-lung)

Distinguished Training and Research

Dr. Hiley graduated with honors from the University of Manchester in 2005 and has trained at some of the world’s leading oncology centers, including:

- The Christie Hospital

- MD Anderson Cancer Centre

- Kings College

- The Royal Marsden

He earned his PhD from the University of London and completed postdoctoral fellowships at the Francis Crick Institute and the UCL Cancer Institute.

Since becoming a consultant in 2018, Dr. Hiley has led the clinical oncology lung team at UCLH. His roles include:

- UCLH Lead for Lung Proton Therapy

- Deputy Lead of Clinical Trials for the CRUK Lung Cancer Centre of Excellence

- NIHR Clinical Research Network Specialty Research Lead in Radiotherapy for North London

Dr. Hiley heads a research group focused on overcoming resistance to cancer treatments and is the principal investigator for numerous clinical trials. His work has been featured in prestigious journals like NEJM, The Lancet, Nature, and Cell. He also contributed to the Royal College of Radiologists Consensus Statement on Radiotherapy for Lung Cancer, setting the standard of practice in the UK.